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Abstract
Background For physicians dealing with patients with a
limited life expectancy, knowing the time to benefit (TTB)
of preventive medication is essential to support treatment
decisions.
Objective The aim of this study was to investigate the
usefulness of statistical process control (SPC) for deter-
mining the TTB in relation to fracture risk with alendronate
versus placebo in postmenopausal women.
Methods We performed a post hoc analysis of the Frac-
ture Intervention Trial (FIT), a randomized, controlled trial
that investigated the effect of alendronate versus placebo
on fracture risk in postmenopausal women. We used SPC,
a statistical method used for monitoring processes for
quality control, to determine if and when the intervention
group benefited significantly more than the control group.
SPC discriminated between the normal variations over time
in the numbers of fractures in both groups and the varia-
tions that were attributable to alendronate. The TTB was
defined as the time point from which the cumulative dif-
ference in the number of clinical fractures remained greater
than the upper control limit on the SPC chart.
Results For the total group, the TTB was defined as 11
months. For patients agedC70 years, the TTB was 8 months
[absolute risk reduction (ARR) = 1.4 %]; for patients aged
\70 years, it was 19 months (ARR = 0.7 %).
Conclusion SPC is a clear and understandable graphical
method to determine the TTB. Its main advantage is that there
is no need to define a prespecified time point, as is the case in
traditional survival analyses. Prescribing alendronate to
patients who are aged C70 years is useful because the TTB
shows that they will benefit after 8 months. Investigators
should report the TTB to simplify clinical decision making.
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Key Points for Decision Makers
Statistical process control is a clear and
understandable method to determine the time to
benefit of preventive drugs.
We showed that in the Fracture Intervention Trial
(FIT), the time to benefit of alendronate for
prevention of fractures was 11 months.
Clinical decision making for an individual patient
with a limited life expectancy can be simplified by
applying the time to benefit.
1 Introduction
The number of drug prescriptions in older patients is large
[1] because the number of diseases increases with age.
Consequently, older patients are prone to possible side
effects of medication because of altered pharmacodynam-
ics and pharmacokinetics [2]. Therefore, medication should
be prescribed only to patients who are likely to benefit. For
physicians dealing with older patients with multiple con-
ditions, it is important to take the life expectancy of the
patient into account, as it is possible that patients will not
live long enough to benefit from preventive medication.
Therefore, knowing the time to benefit (TTB) supports
treatment decisions. The TTB can be defined as an estimate
of the time needed until a treatment becomes significantly
effective in a group of patients [3]. Although it seems clear
that it is important to take the TTB into account when
prescribing medication [4, 5], the concept is seldom men-
tioned in trial results and is even more rarely calculated for
the subpopulation of elderly patients [4, 5]. Answers to
these questions cannot readily be provided by other tradi-
tional techniques, such as survival analysis, because there a
pre-fixed analysis point is used.
Osteoporosis is highly prevalent at older ages; it has
been estimated to affect 55 % of the US population
C50 years of age [6]. There is sufficient evidence from
randomized clinical trials that the current pharmacological
therapies for osteoporosis are effective in preventing new
fractures in older patients as well [6]. Bisphosphonates are
frequently prescribed [7]; therefore, it is important to know
the TTB of this medication.
The aim of this study was to use statistical process
control (SPC) to determine the TTB of alendronate for
fracture risk in postmenopausal women with osteoporosis.
SPC is a statistical method that is used in research for
health care improvements but not often in other branches of
medicine [8]. It is an innovative and easy-to-interpret
method to identify significant variations in clinical out-
comes in a range of health care settings. Usefulness was
assessed by inspecting whether SPC could provide an
answer to the following question: if and when patients
receiving alendronate benefited significantly more than
those receiving placebo. We aimed to calculate the TTB
especially for older adults (aged C70 years) because the
oldest individuals are at highest risk of side effects and a
limited life expectancy.
2 Methods
2.1 Original Data from the FIT Study
Original data from the Fracture Intervention Trial (FIT)
were used to determine the TTB [9, 10]. FIT was a
randomized, placebo-controlled trial investigating the
effect of alendronate versus placebo on the risks of
morphometric vertebral fractures, as well as clinically
evident fractures at all sites in postmenopausal women
(aged 55–80 years). Full details of the study are described
elsewhere [9, 11]. The present analysis was performed in
all patients (n = 3658) with confirmed osteoporosis [ei-
ther a femoral neck bone mineral density (BMD) T score
B22.5 (n = 1631) or at least one morphometric vertebral
fracture (n = 2027)]. The outcome of interest was any
new clinical fracture (either vertebral or non-vertebral). A
clinical fracture was defined as a fracture diagnosed by a
physician and confirmed by written reports or radio-
graphs. We chose the outcome of clinical fracture instead
of morphometric vertebral fracture because for clinical
fracture it was clear at which time point it had developed,
whereas a nonclinical vertebral fracture became visible
only when a radiograph was performed. The analysis was
limited to the first fracture. Patients who did not complete
follow-up were censored when they left the study. Formal
consent or approval was not necessary for this post hoc
analysis.
2.2 Analysis: Statistical Process Control
We assessed the longitudinal effect of alendronate on the
incidence of clinical fractures in postmenopausal women
with osteoporosis, using SPC [12–14].
SPC relies on statistical methods to monitor a series of
measurements (process) to indicate when a structural
change in the measurements, i.e. not due to chance, has
occurred [12–14]. When this happens, it is said that the
process goes from ‘in control’ (stable) to ‘out of control’
[15]. Out of control is determined by analysis of the vari-
ability of the measurements over time. An important tool
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used in SPC to show the results is a graphical chart, called
a ‘control chart’, which plots the measurements (e.g. a
proportion or a mean) over time and uses the observed
variability of these measurements to calculate the limits of
the expected variation [8]. Several types of control
chart are available, depending on the nature of the mea-
surement and the purpose of the study. Generally, the limits
of variation are three adjusted standard deviations (called
‘three sigmas’) from the mean of the measurements. When
measurements cross these limits, then the process is out of
control, otherwise it is stable. The limit of three sigmas was
chosen because SPC implicitly uses multiple tests—one for
every measurement. When the significance level is set at
three sigmas, 99.7 % of values are in the specified range. In
this way, SPC also accounts for multiple testing [16].
In the FIT data, the cumulative difference in the num-
bers of new clinical fractures in the placebo group versus
the treatment group was measured per month and, in a
second analysis, every 2 weeks. These intervals were
chosen because we considered 2 weeks a relevant clinical
interval to see a change. For these time points, the absolute
risk reduction (ARR) was calculated. These intervals were
chosen to define the TTB as precisely as possible. We used
the measurements in the first 6 months to calculate the
control limits. This period was chosen because we
hypothesized that it takes 6 months for the medication to
become effective in improving bone strength; variation
within this period can be seen as physiological fluctuation
not related to the pharmacological effect of bisphospho-
nates [17]. The rate of suppression of bone resorption by
bisphosphonates increases until a limit is reached after
about 3 months; thereafter it remains at a constant level.
Paradoxically, bone formation decreases after commence-
ment of bisphosphonates, as a result of the coupling of
bone formation and resorption in the basic molecular units.
Biochemical markers have shown that the decrease in bone
formation is smaller and lags behind the suppression of
bone resorption [18]. Eventually, a balance between for-
mation and suppression is reached in 3–6 months [19]. For
this study, we used an XmR SPC chart (‘X’ stands for
individual measurements, and ‘mR’ stands for ‘moving
range’). The XmR chart is popular for its ability to visually
depict variation when only one observation exist in each
time period—in our case, the cumulative difference in the
number of fractures per month [16]. This chart has a dis-
tinctive pattern marked by three horizontal reference lines.
The centre line is the average value of the measurements
when the process is in control; the other two reference lines
are the upper and lower control limits, corresponding to the
boundaries beyond which the process will be considered
out of control. The upper and lower control limits are three
sigmas away from the centre line, in order to adjust for
multiple testing.
There are several rules that indicate when a relevant
variation has occurred on a process control chart. Most of
them are designed to identify a trend in the effect rather
than an absolute effect [16]. Because we were interested in
a sustained effect of time (the TTB), we limited the SPC
analysis to one rule: the process being out of control at one
point beyond three sigmas when the next points also
remain beyond three sigmas. Thus, a successful interven-
tion causes the process to go out of control in the direction
of improvement. The TTB—the estimate of time needed
until the treatment group and the placebo group start to
differ in terms of the effect—was defined in this study as
the first month at which the cumulative difference in the
percentages of any clinical fractures between the two study
arms remained greater than three sigmas. In this regard, the
time point that we called the TTB occurred when the dif-
ference in the ARR between the two groups exceeded and
remained greater than three sigmas.
The SPC chart and the ARR calculation are illustrated in
Fig. 1. At time point 6, which corresponded to month 6 of
the study, there were, in total, 1834 patients remaining
under observation in the treatment group and 1813 patients
in the placebo group. Among these patients (at time
point 6) there were nine patients with fractures in the
treatment group and five patients with fractures in the
placebo group. Therefore, the percentages of new patients
Fig. 1 Statistical process control chart of the cumulative absolute
risk reduction (ARR) in clinical fractures in the total group of patients
in the Fracture Intervention Trial (FIT) (n = 3658). The down arrow
at 11 months is the time to benefit, i.e. the first point at which the
difference is greater than the upper control limit (ARR = 1.1 %). The
centre line (dashed horizontal line), upper control limit (upper dotted
horizontal line) and lower control limit (lower dotted horizontal line)
were calculated on the basis of the data from the first 6 months
(indicated by the dashed vertical line)
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with fractures were 0.49 % (9/1834) in the treatment group
and 0.28 % (5/1813) in the placebo group. Thus, the dif-
ference amounted to -0.21 (0.28 - 0.49). The cumulative
difference at month 5 was 0.40; therefore, the new cumu-
lative difference was 0.40 ? (-0.21) = 0.19.
2.3 Subgroup Analysis
Because the incidence of fractures increases with age [20],
older patients in trials are likely to have an increased risk of
fracture in comparison with younger patients. Therefore,
we hypothesized that older patients might have a shorter
TTB than younger patients. We performed a predefined
subgroup analysis for age groups (aged \70 and




In FIT, 3658 patients with osteoporosis were included:
1841 in the alendronate group and 1817 in the placebo
group (Table 1). During the study period, there were 511
primary fractures; 190 patients had two or more reported
fractures. Seventy-six patients died, of whom 20 had a
fracture.
3.2 Statistical Process Control
SPC analysis of the total group showed that the process went
out of control and remained so after 11 months (Fig. 1),
when the cumulative ARR was 1.1 %. This corresponded to
a number needed to treat (NNT) of 100. The TTBwas shorter
for patients aged C70 years (n = 1870; after 8 months,
ARR = 1.4 %, NNT = 71) than for younger patients (after
19 months, ARR = 0.7 %, NNT = 143) (Fig. 2a, b). The
Fig. 2 Statistical process control chart of the cumulative absolute
risk reduction (ARR) in clinical fractures in a patients aged
C70 years (n = 1870) and b patients aged\70 years (n = 1788) in
the Fracture Intervention Trial (FIT). In a, the down arrow at
8 months indicates where the process is out of control (the time to
benefit), i.e. the first point at which the difference is greater than the
upper control limit (ARR = 1.4 %). In b, the down arrow is at
19 months (ARR = 0.7 %). The centre line (dashed horizontal line),
upper control limit (upper dotted horizontal line) and lower control
limit (lower dotted horizontal line) were calculated on the basis of the
data from the first 6 months (indicated by the dashed vertical line)
Table 1 Characteristics of the participants in the Fracture Interven-
tion Trial (FIT): postmenopausal women (n = 3658) aged
55–80 years with confirmed osteoporosis [either a femoral neck bone
mineral density (BMD) T score B-2.5 (n = 1631) or at least one
morphometric vertebral fracture (n = 2027)]. The main study
outcome is also reported
Characteristic Alendronate group, n = 1841 Placebo group, n = 1817 P value
Age [years; mean (SD)] 69.3 (6.0) 69.5 (5.9)
Clinical fracture after the age of 45 years [n (%)] 935 (51) 907 (49)
Femoral neck BMD T-score [mean (SD)] -2.74 (0.55) -2.76 (0.55)
Clinical fracture during 36-month follow-up [n (%)] 215 (12) 296 (16) \0.001
Death during follow-up [n (%)] 40 (2) 36 (2) 0.69
SD standard deviation
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results were similar when two measure points per month
were used (data not shown). At 3 years (the end of follow-
up), the ARR in FIT was 4 %, corresponding to an NNT of
25.
4 Discussion
Statistical process control is a graphical method with a
clear and understandable chart for calculating the TTB on
data from a randomized, controlled trial. With this method,
we calculated that the TTB of alendronate for prevention of
osteoporotic clinical fractures was 11 months in a popu-
lation of postmenopausal women with osteoporosis. In the
subgroup analysis of older participants (aged C70 years),
the TTB was 8 months.
Although much literature on osteoporosis therapy is
available, few authors have reported an analysis before
the end of follow-up, and even fewer have reported a
time-to-event analysis of clinical fractures. Six studies
reported the outcome before the end of follow-up, within
1 year [4, 5, 10, 21, 22], by means of a survival analysis.
In all of these cases, a predefined point was used to
perform a log rank test. One study used a post hoc
analysis at 3 and 6 months to determine an early effect
[22]. In all seven studies, the absolute effect at the time
of significance was small.
The advantage of SPC in comparison with the most
frequently used survival analysis is that the measure point
at which the difference is greater than three sigmas is
directly visible in the graph and can therefore be detected
at a glance, while in the survival analysis, multiple analyses
have to be done. Moreover, for a logistic regression model,
it is necessary to check the assumptions of the model; when
there is a U-shaped response, this will not become clear in
a logistic regression model, whereas in a SPC graph, it will
immediately become clear whether it is a sustained effect.
In short, logistic regression and SPC are two useful and
complementary tools to be considered by the modeller.
SPC is less versatile in terms of modelling covariates but,
in doing so, it does not impose distributional restrictions on
the monitored quantities over time, and it does provide an
intuitive machinery geared towards detecting changes over
time. Other tools, such as logistic regression, allow for
more versatile modelling and interpretation of the coeffi-
cients but require assumptions and various modelling
choices. In addition, such models, if sound, allow for
interpolation and extrapolation. Knowing the TTB allows
for an informed prediction on when (and how large) a
benefit is expected to be observed in a patient, and hence it
informs decision making. In addition, such answers may
inform the economical follow-up time in clinical trials.
SPC is convenient to use; there are simple tools available
for creating the plots, and learning the method does not
require a lot of training.
At the TTB—the time point at which the numbers of
fractures in the placebo group and the alendronate group
started to differ significantly—the reported ARRs were
small. In the follow-up after this point, the ARR in clinical
fractures increased to 4.5 % after 3 years because of the
ongoing effect of alendronate on bone. The clinical deci-
sion to start a treatment depends on the patient’s and
physician’s preferences and the patient’s clinical condition
[23]. With knowledge of the TTB, a treatment can be better
adjusted to patients with a limited life expectancy, although
estimating this has proven to be difficult [24]. The SPC
graph could also be presented as the number needed to treat
(NNT = 1/ARR) over time. Taking into account a
patient’s life expectancy, the TTB and the NNT could help
in clinical decision making [25]. Therefore, we suggest that
the authors of randomized, controlled trials report these
data as well. Furthermore, it is known that the medication
adherence to bisphosphonates is low [26]. This could
possibly lead to underestimation of the TTB, as the number
of fractures in the intervention groups would be decreased.
The age range of the participants in FIT was 55–80 years
[29]. Our predefined subgroup of patients aged C70 years
was therefore not older than 81 years during the first year
of follow-up. Because the TTB was dependent on the
a priori chance of having a (vertebral) fracture, and the
chance of a (vertebral) fracture increases with age (with the
highest a priori chance existing in patients aged
[80 years), we can assume that the TTB for alendronate
may be even shorter for the oldest old and in an older
geriatric population with high risks of falls and fractures.
As a result, we conclude that not discussing use of bis-
phosphonates in older patients with a life expectancy of[8
months is not evidence-based clinical practice when
reducing the risk of additional fractures is the patient’s
preferred clinical goal. Fractures are associated with sig-
nificant mortality and morbidity, and represent a substantial
economic burden to society [27].
SPC is a statistical method that was originally designed
for quality control to monitor and control a process; it
provides a signal when abnormal variation in the process is
detected. There are several rules that indicate when a
process is out of control. Apart from the rule we used to
indicate when the process was out of control (i.e. one point
being greater than three sigmas), there are frequently used
rules that are able to detect a trend over time. This shows
the versatility of SPC. In our application, we used only the
rule that we felt was relevant to this specific application. If
one wants to detect the first point of change (regardless of
magnitude), then one may use other rules. If we had used
these trend rules, we would have found an earlier effect.
Using SPC in this way could help in defining the time
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period when any effect is lacking for certain. However, this
early effect would correspond with a very small absolute
effect, which might not be clinically relevant. In cohort
studies, one could think of many alternative ways to use
SPC—for example, to measure treatment and side effects
over time, or it could be used in the decision to stop a trial
early because an effect has already been achieved.
A limitation of applying SPC for defining the TTB is that
when the first measurements in the study reflect an unsta-
ble process, it is impossible to define the upper and lower
limits. If an early effect of treatment is expected, one should
find an alternative way to define the central line and its
limits—for example, by using different time intervals
between measurements, or preferably by using data before
the start of the treatment. Because we performed a post hoc
analysis, we had to define a period to define the limits,
which, although well considered, could be debated. For
instance, in the subgroup analysis, the centre line lay above
zero for the group aged C70 years and below zero for the
younger group, suggesting minimal differences in fracture
risks between the treatment and placebo groups. We assume
that these differences were caused by coincidence rather
than by real differences between the groups, because we
checked both groups’ patient characteristics, such as age and
number of falls (data not shown). Ideally, the limit should be
at zero and should be calculated before the start of treatment.
5 Conclusion
Statistical process control is a novel method to define the
TTB for medication used to treat and prevent clinical
outcomes. Its main advantages are that it becomes clear at a
glance when the effect occurs, and no predefined endpoints
are necessary to define the TTB. We would encourage
scientists to report the TTB, especially in studies of pre-
ventive medication in older patients. Clinical decision
making can be made more evidence based by applying the
TTB and ARR, so that the pros and cons of initiating or
stopping medication can be weighed for an individual
patient with a limited life expectancy.
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